Merck Wins Another FDA Approval for Blockbuster Keytruda
Merck & Co arrived just two months after GSK celebrated a positive phase III result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer. Keytruda (pembrolizumab) from Merck improved progression-free survival (PFS) versus chemotherapy alone in patients with stage 3 to 4 or recurrent endometrial carcinoma, regardless of mismatch repair status, in the late-stage NRG-GY018 trial.
The findings follow GSK's announcement that Jemperli (dostarlimab) plus chemo performed well in the RUBY trial in patients with primary advanced or recurrent endometrial cancer, becoming the first...
